Aug 2026· IEEE transactions on computational biology and bioinformatics· Vol PP· 0 citations
Medicine
TL;DR
Overall, TriOmicNet provides an integrative framework for cancer driver gene prioritization and may support further investigation of cancer biomarkers and therapeutic targets.
Abstract
Cancer is a complex disease driven by genetic mutations, and identifying driver genes is crucial for discovering key biomarkers and developing personalized therapies. In this study, we propose TriOmicNet, a multi-layer network diffusion method that integrates gene mutation, gene expression, and miRNA expression data. Unlike traditional methods that rely on a single data source, TriOmicNet combines three scoring mechanisms: regulatory potential, control ability, and multi-network diffusion. In addition, a node-scoring strategy is used to determine the seed nodes of the random walk algorithm. Comparative results with seven state-of-the-art methods show that TriOmicNet achieves competitive performance across several evaluation metrics and identifies potential driver genes that other methods overlook or rank lower. Ablation results indicate that the multi-network diffusion score provides the dominant predictive signal in some settings, while the other two scores provide complementary evidence rather than consistent F1 improvements. In the BRCA, LUAD, and PRAD datasets, TriOmicNet identified 121, 135, and 148 potential driver genes, respectively, that are not included in the benchmark driver gene databases. Overall, TriOmicNet provides an integrative framework for cancer driver gene prioritization and may support further investigation of cancer biomarkers and therapeutic targets.
This chapter provides a comprehensive technical protocol for predicting CDGs using a Graph Convolutional Network (GCN) and guides the reader through hyperparameter optimization, model training, and performance evaluation, while discussing practical considerations related to generalization, computational cost, and inter...
Renan Soares de Andrades, M. Recamonde-Mendoza· Methods in molecular biology· 0 citations
Complex diseases arise from perturbations in interconnected biological networks rather than isolated genetic defects. Network-based approaches provide a systematic framework for understanding disease mechanisms through protein-protein interaction data, yet most existing methods are developed and validated on a single...
Sveva Bonomi, Loris Bottelli, E. Oltra et al.· Scientific Reports· 0 citations
Biomarker discovery from high-dimensional RNA sequencing data remains challenging. Conventional methods such as differential expression analysis, pairwise protein-protein interaction networks, and weighted gene co-expression network analysis suffer from false-positive interactions, transitivity-driven noise, and arbitr...
M. Gupta, Mainak Paul, Soumen Kumar Pati· bioRxiv· 0 citations
Background Reversing the tumor phenotype is a long-standing challenge in cancer biology. Although GRNs comprise thousands of genes, normal and tumor tissues occupy distinct, low-dimensional attractors in expression space, raising the possibility that targeting a few key genes could induce widespread transcriptional cha...
Gabriel Gil, Rolando Pérez, Augusto Gonzalez· Frontiers in Systems Biology· 0 citations
Genetic compensation plays a critical role in mitigating the effects of deleterious mutations in genetic diseases. Identifying functionally compensatory gene relationships represents a promising strategy for discovering therapeutic targets in inherited genetic disorders and cancer. We present a novel approach that comb...
Federico García-Criado, J. Pérez-García, E. Rojano et al.· Artif. Intell. Medicine· 0 citations
Results indicate that VARION’s GIS-weighted centroid architecture enables individual-patient molecular subtyping that outperforms existing NBS and graph-learning clustering approaches, with high sensitivity for clinically actionable rare subtypes and robust cross- platform generalization.
Taesoo Kwon, Y. Park, J. Choi· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.